Marksans Pharma Share Price | Marksans Pharma Stock Screener
MARKSANS
Pharmaceuticals
Share Price NSE
₹249.27
▼
-5.52 (-2.17%)
Share Price BSE
₹248.90
▼
-5.55 (-2.18%)
As of May 27, 2026, the Marksans Pharma share price (NSE: MARKSANS) is ₹249.27 on NSE and ₹248.90 on BSE, down 2.17% from the previous close, with shares trading between ₹247.01 and ₹264.40, and a 52-week range of ₹156.89–₹263.55.
Check MARKSANS 52-week high low for the annual price range and momentum.
Use the Marksans Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Marksans Pharma Market Cap
₹9,603.37 Cr.
MARKSANS P/E Ratio (TTM)
27.07
Marksans Pharma P/B Ratio
3.64
EPS (TTM)
₹8.40
Dividend Yield
0.37%
Debt to Equity
0.12
MARKSANS 52 Week High
₹263.55
Marksans Pharma 52 Week Low
₹156.89
Operating Margin
21.00%
Profit Margin
14.71%
MARKSANS Revenue (TTM)
₹775.00
EBITDA
₹181.00
Net Income
₹114.00
Total Assets
₹3,240.00
Total Equity
₹2,489.00
Marksans Pharma Share Price Chart
Screen Marksans Pharma share price with an interactive chart. Analyse MARKSANS price trends and volatility across different timeframes.
Marksans Pharma Company Profile - Fundamental Screener
Screen Marksans Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MARKSANS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE750C01026
Marksans Pharma Balance Sheet Screener
Screen MARKSANS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 3,240 | 2,681 | 2,190 | 1,640 | 1,229 | 903 | 804 | 732 | 752 | 722 |
| Current Assets | 2,204 | 1,863 | 1,675 | 1,201 | 903 | 594 | 531 | 451 | 484 | 440 |
| Fixed Assets | 982 | 776 | 486 | 428 | 309 | 303 | 270 | 279 | 267 | 270 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 273 | 205 | 84 | 61 | 25 | 25 | 18 | 17 | 16 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 2,489 | 2,086 | 1,765 | 1,223 | 905 | 649 | 553 | 480 | 440 | 463 |
| Share Capital | 45 | 45 | 45 | 41 | 41 | 41 | 41 | 41 | 41 | 53 |
| Reserves & Surplus | 2,422 | 2,020 | 1,700 | 1,068 | 846 | 595 | 502 | 430 | 393 | 401 |
Marksans Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Marksans Pharma income statement and profit fundamentals.
Analyze MARKSANS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Marksans Pharma share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 775 | 742 | 626 | 724 | 710 | 642 | 606 | 577 | 591 | 550 | 510 | 497 | 498 | 467 | 450 |
| Expenses | 594 | 576 | 520 | 582 | 543 | 495 | 462 | 450 | 453 | 417 | 398 | 376 | 403 | 372 | 361 |
| EBITDA | 181 | 166 | 106 | 142 | 167 | 147 | 143 | 126 | 138 | 133 | 112 | 121 | 94 | 94 | 89 |
| Operating Profit % | 21.00% | 20.00% | 16.00% | 18.00% | 20.00% | 23.00% | 22.00% | 20.00% | 23.00% | 21.00% | 20.00% | 23.00% | 16.00% | 18.00% | 17.00% |
| Depreciation | 24 | 27 | 23 | 23 | 21 | 20 | 20 | 21 | 22 | 18 | 14 | 14 | 13 | 14 | 11 |
| Interest | 6 | 6 | 6 | 3 | 3 | 3 | 3 | 5 | 3 | 2 | 2 | 2 | 2 | 3 | 2 |
| Profit Before Tax | 151 | 133 | 77 | 116 | 143 | 125 | 120 | 100 | 113 | 114 | 97 | 104 | 79 | 78 | 76 |
| Tax | 37 | 34 | 18 | 25 | 38 | 27 | 31 | 23 | 30 | 30 | 26 | 22 | 17 | 18 | 16 |
| Net Profit | 114 | 99 | 58 | 91 | 105 | 98 | 89 | 78 | 83 | 84 | 70 | 83 | 62 | 60 | 60 |
| EPS | 2.50 | 2.17 | 1.29 | 2.00 | 2.31 | 2.13 | 1.96 | 1.73 | 1.84 | 1.84 | 1.52 | 1.97 | 1.56 | 1.52 | 1.46 |
Marksans Pharma Cash Flow Screener - Liquidity Fundamentals
Screen MARKSANS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 207 | 230 | 237 | 99 | 179 | 233 | 27 | 50 | 14 | 31 |
| Investing Activities | -49 | -141 | -259 | -84 | -45 | -60 | -14 | -39 | -21 | -123 |
| Financing Activities | -65 | -69 | 198 | 80 | -15 | -114 | -21 | 3 | -4 | -58 |
| Net Cash Flow | 93 | 21 | 176 | 94 | 119 | 60 | -7 | 15 | -10 | -150 |
Marksans Pharma Shareholding Pattern Screener
See Marksans Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Marksans Pharma promoter holding and ownership changes for MARKSANS on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| FII Holding | 16.76% | 8.12% | 16.92% | 19.88% | 22.20% | 21.96% | 21.31% | 18.60% |
| DII Holding | 6.57% | 5.91% | 5.28% | 5.50% | 4.56% | 4.30% | 4.10% | 3.75% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 28.33% | 28.98% | 29.53% | 26.75% | 25.77% | 26.24% | 26.77% | 29.47% |
| Other Holding | 4.45% | 13.11% | 4.40% | 4.00% | 3.59% | 3.63% | 3.95% | 4.31% |
| Shareholder Count | 246,279 | 255,153 | 265,788 | 256,221 | 257,273 | 259,813 | 248,845 | 235,500 |
Marksans Pharma Share Dividend Screener - Share Yield Analysis
Check Marksans Pharma dividend history with payout and yield data.
View Marksans Pharma dividend details including ex-dates and amounts for MARKSANS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.80 | 0.51% |
| 2024-March | ₹0.60 | 0.27% |
| 2023-March | ₹0.50 | 0.33% |
| 2022-March | ₹0.25 | 0.34% |
| 2021-March | ₹0.25 | 0.55% |
| 2020-March | ₹0.10 | 0.20% |
| 2019-March | ₹0.05 | 0.36% |
| 2018-March | ₹0.05 | 0.20% |
| 2017-March | ₹0.05 | 0.16% |
Marksans Pharma Stock Index Membership
See which indices include Marksans Pharma stock.
Check MARKSANS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Marksans Pharma Market Events Screener - Corporate Actions
Get Marksans Pharma corporate actions including splits, bonuses, and buybacks.
Check Marksans Pharma stock events that may affect MARKSANS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.60 /share | 73.31% | ||
| Dividend | ₹ 0.25 /share | -3.92% | ||
| Annual General Meeting | NA | 50.49% | ||
| 2026-05-26 | 2026-05-26 | Quarterly Result Announcement | NA | 4.12% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | -0.95% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 9.28% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -11.45% |
| 2025-08-08 | 2025-08-08 | Annual General Meeting | NA | -16.51% |
| 2025-08-01 | 2025-08-01 | Dividend | ₹ 0.80 /share | -5.63% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 7.03% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 3.18% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 8.46% |
| 2023-06-07 | 2023-06-07 | Dividend | ₹ 0.50 /share | 18.20% |
| 2022-08-19 | 2022-08-23 | Dividend | ₹ 0.25 /share | 8.78% |
Marksans Pharma Competitors Screener - Peer Comparison
Screen MARKSANS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,581 | 41.43 | 54,729 | 9.71% | 10,980 | 54.75 |
| Divis Laboratories | 182,828 | 73.47 | 9,712 | 18.67% | 2,191 | 66.48 |
| Torrent Pharmaceuticals | 151,833 | 66.60 | 11,539 | 6.99% | 1,911 | 61.90 |
| Cipla | 113,025 | 29.32 | 27,712 | -2.46% | 3,783 | 61.92 |
| Dr Reddys Laboratories | 109,105 | 26.47 | 33,593 | -0.44% | 3,998 | 52.61 |
| Zydus Life Science | 104,543 | 20.35 | 26,720 | 13.65% | 5,242 | 69.40 |
| Lupin | 104,288 | 19.51 | 27,488 | 19.98% | 5,345 | 47.33 |
| Mankind Pharma | 102,351 | 53.58 | 14,278 | 12.03% | 1,750 | 62.34 |
| Aurobindo Pharma | 85,000 | 25.77 | 32,346 | 9.43% | 3,484 | 52.91 |
| Laurus Labs | 72,530 | 81.91 | 6,813 | 21.03% | 884 | 77.10 |
Marksans Pharma Company Announcements - News Screener
Screen MARKSANS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-25 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-12 | Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results And To Consider Recommendation Of Dividend If Any For The Financial Year Ended March 31 2026 | - |
| 2026-04-09 | Compliances-Certificate Under Reg. 74 (5) Of SEBI (DP) Regulations 2018 | - |
| 2026-04-01 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-11 | Intimation Regarding Opening Of Special Window For Re-Lodgment Of Transfer Requests Of Physical Shares | - |
| 2026-03-10 | Investec India Promoter & Founder Conference 2026 | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-05 | Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025 | - |
| 2026-02-05 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025 | - |
| 2026-01-27 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-01-09 | Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter Ended December 31 2025 | - |
| 2025-12-26 | Closure of Trading Window | - |